Citigroup Maintains Neutral on Quest Diagnostics, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $135 to $145.

April 24, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Neutral rating on Quest Diagnostics and raises the price target to $145.
The increase in the price target by Citigroup reflects a positive outlook on Quest Diagnostics' financial performance and market position. This adjustment suggests that Citigroup sees potential for Quest Diagnostics' stock price to rise, aligning with the new target. However, the Neutral rating indicates that there may be factors or uncertainties that could limit significant upside or downside in the short term. Investors might view this as a sign of stability with a potential for modest growth.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100